Linear Clinical Research
Nedlands, Western Australia, Australia
32 recruiting
Showing 1–20 of 60 trials
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled77 locationsNCT04585750
Recruiting
Phase 1Phase 2
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled28 locationsNCT05320198
Recruiting
Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines308 enrolled37 locationsNCT06233942
Recruiting
Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Advanced Solid TumorSolid Tumor
BeOne Medicines337 enrolled28 locationsNCT05981703
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled155 locationsNCT06742996
Recruiting
Phase 1
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines153 enrolled26 locationsNCT06598800
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
Myeloid Malignancy
BeOne Medicines118 enrolled4 locationsNCT07619287
Recruiting
Phase 1
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled14 locationsNCT06756932
Recruiting
Phase 1
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines525 enrolled98 locationsNCT06589596
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines260 enrolled46 locationsNCT04771130
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled197 locationsNCT06973187
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 2
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
CTCL
Prescient Therapeutics, Ltd.115 enrolled15 locationsNCT06854653
Recruiting
Phase 1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Lymphoma, Non-HodgkinB-cell LymphomaWaldenstrom Macroglobulinemia+4 more
Eli Lilly and Company215 enrolled50 locationsNCT07101328
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled38 locationsNCT06465069
Recruiting
Phase 1
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Advanced Solid TumorHNSCCPDAC
Adcendo ApS210 enrolled12 locationsNCT06597721
Recruiting
Phase 1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
LymphomaLymphoma, Non-Hodgkin
Treeline Biosciences, Inc.180 enrolled14 locationsNCT07082803
Recruiting
Phase 1
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 1
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Colorectal, CancerTriple Negative Breast Cancer(TNBC)Urothelial Cancer
Context Therapeutics Inc.162 enrolledNCT07545122